Being metabolized only to a small extent, the substance has a low potential for interactions. In studies, inhibitors of the liver enzymes CYP3A4, CYP2C19, and CYP2C9, as well as the CYP3A4 inducer rifampicin, had no relevant influence on<unk>  concentrations in the bloodstream. While<unk>  blocks a number of transporter proteins in vitro, clinically relevant interactions via this mechanism are considered very unlikely, except perhaps for the cation transporter SLC22A1 (OCT1). An additive effect with other immunosuppressants cannot be excluded.
Baricitinib
Abrocitinib
Erdafitinib
Upadacitinib
Gilteritinib
Delgocitinib
Brigatinib
Selpercatinib